Transgene Sa Stock Price To Sales
| TRGNF Stock | USD 1.59 0.00 0.00% |
Transgene SA fundamentals help investors to digest information that contributes to Transgene's financial success or failures. It also enables traders to predict the movement of Transgene Pink Sheet. The fundamental analysis module provides a way to measure Transgene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Transgene pink sheet.
Transgene |
Transgene SA Company Price To Sales Analysis
Transgene's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Transgene Price To Sales | 10.71 X |
Most of Transgene's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Transgene SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Transgene SA has a Price To Sales of 10.7104 times. This is 49.95% lower than that of the Healthcare sector and 89.12% lower than that of the Biotechnology industry. The price to sales for all United States stocks is 6.21% higher than that of the company.
Transgene Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Transgene's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Transgene could also be used in its relative valuation, which is a method of valuing Transgene by comparing valuation metrics of similar companies.Transgene is currently under evaluation in price to sales category among its peers.
Transgene Fundamentals
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 152.15 M | |||
| Shares Outstanding | 100.2 M | |||
| Shares Owned By Institutions | 1.70 % | |||
| Price To Earning | (7.42) X | |||
| Price To Book | 0.02 X | |||
| Price To Sales | 10.71 X | |||
| Revenue | 9.99 M | |||
| Gross Profit | (15.87 M) | |||
| EBITDA | (16.55 M) | |||
| Net Income | (19.54 M) | |||
| Cash And Equivalents | 49.57 M | |||
| Cash Per Share | 0.50 X | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 4.27 X | |||
| Book Value Per Share | 0.55 X | |||
| Cash Flow From Operations | (31.94 M) | |||
| Earnings Per Share | (0.23) X | |||
| Number Of Employees | 143 | |||
| Beta | 0.79 | |||
| Market Capitalization | 212.74 M | |||
| Total Asset | 101.84 M | |||
| Retained Earnings | (500 M) | |||
| Working Capital | 27 M | |||
| Current Asset | 51 M | |||
| Current Liabilities | 24 M | |||
| Z Score | -5.6 | |||
| Net Asset | 101.84 M |
About Transgene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Transgene SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transgene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transgene SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Transgene Pink Sheet
Transgene financial ratios help investors to determine whether Transgene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.